These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30942058)

  • 21. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
    Tian T; Huang R; Liu B
    Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
    Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
    J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy.
    Zhao T; Liang J; Li T; Gao W; Lin Y
    Chin J Cancer Res; 2017 Jun; 29(3):213-222. PubMed ID: 28729772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
    Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
    Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
    Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of thyroglobulin measurement with fine-needle aspiration biopsy for lymph node metastases in patients with a history of differentiated thyroid cancer.
    Zhang HS; Wang RJ; Fu QF; Gao S; Sun BT; Sun H; Ma QJ
    Asian Pac J Cancer Prev; 2014; 15(24):10905-9. PubMed ID: 25605199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer.
    Kowalska A; Pałyga I; Gąsior-Perczak D; Walczyk A; Trybek T; Słuszniak A; Mężyk R; Góźdź S
    PLoS One; 2015; 10(7):e0133852. PubMed ID: 26230494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later.
    Melo M; Costa G; Ribeiro C; Carrilho F; Martins MJ; da Rocha AG; Sobrinho-Simões M; Carvalheiro M; Soares P
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4364-72. PubMed ID: 24037891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preradioactive Iodine Thyroglobulin Levels as Predictors of Metastasis in Well-Differentiated Thyroid Carcinoma Patients.
    Darmawan B; Sari M; Susilo S; Kartamihardja AHS
    World J Nucl Med; 2022 Dec; 21(4):296-301. PubMed ID: 36398311
    [No Abstract]   [Full Text] [Related]  

  • 35. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
    Pitoia F; Abelleira E; Cross G
    Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection.
    Moon JH; Choi JY; Jeong WJ; Ahn SH; Lee WW; Kim KM; Choi SH; Lim S; Park YJ; Yi KH; Park do J; Jang HC
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):459-65. PubMed ID: 26833982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma.
    Ronga G; Filesi M; Ventroni G; Vestri AR; Signore A
    Eur J Nucl Med; 1999 Nov; 26(11):1448-52. PubMed ID: 10552086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of Stimulated Thyroglobulin Levels at the Time of Radioiodine Administration in Differentiated Thyroid Cancer.
    Spaas M; Decallonne B; Laenen A; Billen J; Nuyts S
    Eur Thyroid J; 2018 Aug; 7(4):211-217. PubMed ID: 30283740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
    Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
    Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
    Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
    Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.